Barcelona, Spain

Jordi Coll Colomer


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jordi Coll Colomer

Introduction

Jordi Coll Colomer is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in formulations that address specific medical needs. His work exemplifies the intersection of innovation and practical application in healthcare.

Latest Patents

Jordi Coll Colomer holds a patent for a pharmaceutical formulation comprised of polymyxin and trimethoprim. This formulation includes 0.005-1.0% of trimethoprim or a pharmaceutically acceptable salt thereof, 0.01-0.3% of polymyxin or a pharmaceutically acceptable salt thereof, and 0.001-5% of a steroidal or non-steroidal anti-inflammatory drug. Additionally, it may contain various ingredients such as isotonizing agents, pH buffers, viscosity modifying agents, wetting agents, chelating agents, anti-oxidants, preservatives, and vehicles. The formulation is designed to have a pH between 4 and 8.5 and is applicable in the treatment of ophthalmic and otic infections accompanied by inflammation.

Career Highlights

Jordi is associated with Laboratorios Cusi, S.A., where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing treatment options for patients suffering from infections and inflammation.

Collaborations

Throughout his career, Jordi has collaborated with talented professionals such as Michael Van Bergamini and Teresa Borras Sanjurjo. These collaborations have enriched his research and contributed to the success of his projects.

Conclusion

Jordi Coll Colomer's innovative work in pharmaceutical formulations highlights his commitment to improving healthcare solutions. His contributions are vital in addressing specific medical challenges, showcasing the importance of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…